Skip to main content
European Commission logo print header

Commercial feasibility of triggered liposomal drug delivery by means of MOdulated CHAnnels

Objectif

The clinical use of most conventional therapies is limited either by insufficient therapeutic drug concentrations at the target tissue or the severe toxic effects of the drug on healthy tissues. The encapsulation of the drug into a liposome as a carrier and its selective delivery to the affected area is one of the solutions. Several liposomal drug formulations have been approved as anticancer therapeutics however, their clinical significance has been limited by slow passive release of the drug at the target site. The idea of ERC-PoC project is to incorporate an engineered ion channel into liposomes as a sensory valve for triggered release of the liposomal content at the target site. The unique advantage of this system is the ability to make liposomes responsive towards a signal with a sensitivity that is not possible to reach with current available systems. This makes the channels excellent candidates for use in drug carriers such as liposomes and exosomes for stimulus-induced drug release. This IP protected technology (two patents) has shown its technological feasibility in the ERC project. Within the ERC-PoC project we want to explore how we are able to enter the market by developing a sound business plan, IPR strategy, market assessment and a product development plan. The outcomes will be consolidated in a sound business plan that will be presented to venture capitalists or other strategic partners.

Appel à propositions

ERC-2011-PoC
Voir d’autres projets de cet appel

Institution d’accueil

RIJKSUNIVERSITEIT GRONINGEN
Contribution de l’UE
€ 146 433,00
Adresse
Broerstraat 5
9712CP Groningen
Pays-Bas

Voir sur la carte

Région
Noord-Nederland Groningen Overig Groningen
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Dick Veldhuis (Dr.)
Liens
Coût total
Aucune donnée

Bénéficiaires (1)